US EditionPublished • loading... • Updated
J&J sees AI halving the time to generate drug development leads
The company said AI has also cut clinical trial report writing from 700 hours to about 15 minutes.
- On Monday, Johnson & Johnson announced it is using artificial intelligence to halve the time required to generate new drug leads, with CIO Jim Swanson noting accelerated development for compounds in oncology and immunology.
- Moving past the patent expiration of Stelara, the company is leveraging artificial intelligence to optimize workflows amid high costs of drug development, where bringing a new drug to market typically requires a decade and billions in investment.
- Clinical trial report preparation, which traditionally takes 700 to 900 hours, has been reduced to about 15 minutes through artificial intelligence, while Swanson noted the company also uses the technology to streamline regulatory documents and optimize manufacturing.
- Beyond drug discovery, J&J is applying artificial intelligence to help surgeons map hearts for arrhythmia procedures and improve precision in joint replacements, while the technology accelerates enrollment for diverse patient populations in clinical studies, Swanson said.
- Rather than replacing employees, Swanson views artificial intelligence as an additional skill set for the company's about 4,000 information technology staff, emphasizing that while the technology cannot discover products outright, it screens the "potential universe" for promising compounds to optimize development.
Insights by Ground AI
6 Articles
6 Articles
Coverage Details
Total News Sources6
Leaning Left0Leaning Right3Center3Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
